Literature DB >> 7756662

Antisickling effects of 2,3-diphosphoglycerate depletion.

W N Poillon1, B C Kim, R J Labotka, C U Hicks, J A Kark.   

Abstract

Elevation of 2,3-bisphosphoglycerate (2,3-DPG) in sickle erthrocytes (SS RBCs) and concomitant acidification of the cell interior promote polymerization by decreasing the solubility (csat) of deoxyhemoglobin S. The antisickling effect of 2,3-DPG depletion was evaluated after activation of the 2,3-DPG phosphatase activity of bisphosphoglycerate mutase by glycolate-2-phosphate, leading to rapid loss of intracellular 2,3-DPG. To ensure its maximal reduction in a physiologic medium, isosmotic CO2/bicarbonate-buffered saline, pH 7.0, was used. Substitution of K+ for Na+ as the major extracellular cation suppressed K:Cl cotransport, prevented cell shrinkage, and allowed demonstration of the full antisickling effect of 2,3-DPG depletion. The modest effect on solubility per se of removing intraerythrocytic 2,3-DPG (delta Csat = 1.6 g/dL) was amplified into a much larger antisickling effect by interaction with three other cellular variables affecting solubility and polymer content (intracellular pH, O2 saturation, and mean cell hemoglobin concentration). Acting in concert, these four antisickling effects (three solubilizing, one osmotic) reduced polymer fraction of glycolate-treated SS RBCs by 32% to 63%, with a concomitant decrease in sickling of 46% to 95% at the nominal pO2 of the microcirculation (20 mm Hg). A decrement in sickling of this magnitude should significantly ameliorate the vasoocclusive severity of sickle cell disease.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7756662

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  18 in total

1.  Low concentrations of nitric oxide increase oxygen affinity of sickle erythrocytes in vitro and in vivo.

Authors:  C A Head; C Brugnara; R Martinez-Ruiz; R M Kacmarek; K R Bridges; D Kuter; K D Bloch; W M Zapol
Journal:  J Clin Invest       Date:  1997-09-01       Impact factor: 14.808

2.  Detrimental effects of adenosine signaling in sickle cell disease.

Authors:  Yujin Zhang; Yingbo Dai; Jiaming Wen; Weiru Zhang; Almut Grenz; Hong Sun; Lijian Tao; Guangxiu Lu; Danny C Alexander; Michael V Milburn; Louvenia Carter-Dawson; Dorothy E Lewis; Wenzheng Zhang; Holger K Eltzschig; Rodney E Kellems; Michael R Blackburn; Harinder S Juneja; Yang Xia
Journal:  Nat Med       Date:  2010-12-19       Impact factor: 53.440

Review 3.  Regulation of K-Cl cotransport: from function to genes.

Authors:  N C Adragna; M Di Fulvio; P K Lauf
Journal:  J Membr Biol       Date:  2004-10-01       Impact factor: 1.843

Review 4.  Treating sickle cell disease by targeting HbS polymerization.

Authors:  William A Eaton; H Franklin Bunn
Journal:  Blood       Date:  2017-04-06       Impact factor: 22.113

5.  FT-4202, an oral PKR activator, has potent antisickling effects and improves RBC survival and Hb levels in SCA mice.

Authors:  Archana Shrestha; Mengna Chi; Kimberly Wagner; Astha Malik; Jennifer Korpik; Adam Drake; Keertik Fulzele; Sylvie Guichard; Punam Malik
Journal:  Blood Adv       Date:  2021-05-11

Review 6.  Adenosine signaling in normal and sickle erythrocytes and beyond.

Authors:  Yujin Zhang; Yang Xia
Journal:  Microbes Infect       Date:  2012-05-23       Impact factor: 2.700

7.  Mitapivat increases ATP and decreases oxidative stress and erythrocyte mitochondria retention in a SCD mouse model.

Authors:  Zenaide M N Quezado; Sayuri Kamimura; Meghann Smith; Xunde Wang; Michael R Heaven; Sirsendu Jana; Sebastian Vogel; Patricia Zerfas; Christian A Combs; Luis E F Almeida; Quan Li; Martha Quezado; Iren Horkayne-Szakaly; Penelope A Kosinski; Shaoxia Yu; Unnati Kapadnis; Charles Kung; Lenny Dang; Paul Wakim; William A Eaton; Abdu I Alayash; Swee Lay Thein
Journal:  Blood Cells Mol Dis       Date:  2022-03-12       Impact factor: 2.372

Review 8.  Therapeutic strategies to alter the oxygen affinity of sickle hemoglobin.

Authors:  Martin K Safo; Gregory J Kato
Journal:  Hematol Oncol Clin North Am       Date:  2014-01-21       Impact factor: 3.722

Review 9.  Impact of hemoglobin biophysical studies on molecular pathogenesis and drug therapy for sickle cell disease.

Authors:  William A Eaton
Journal:  Mol Aspects Med       Date:  2021-07-14

Review 10.  Research in Sickle Cell Disease: From Bedside to Bench to Bedside.

Authors:  Gabriel Salinas Cisneros; Swee Lay Thein
Journal:  Hemasphere       Date:  2021-06-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.